Estriol add-back therapy in the long-acting gonadotropin-releasing hormone agonist treatment of uterine leiomyomata

Gynecological Endocrinology

Volumn 13, Issue 6, 1999, Pages 382-389

  Nakayama, H ^a   Yano, T ^a   Sagara, Y ^a   Kikuchi, A ^a   Ando, K ^a   Wang, Y ^a   Watanabe, M ^a   Matsumi, H ^a   Osuga, Y ^a   Momoeda, M ^a   Taketani, Y ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Add back therapy; Bone; Bone metabolism; Bone mineral density (BMD); Estriol; Gonadotropin releasing hormone (GnRH) agonist; Uterine leiomyomata

Indexed keywords

ALKALINE PHOSPHATASE; DEOXYPYRIDINOLINE; ESTRIOL; LEUPRIN; LEUPRORELIN; OSTEOCALCIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BONE ATROPHY; BONE DENSITY; BONE MINERAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; HUMAN; LUMBAR SPINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRANSVAGINAL ECHOGRAPHY; UTERUS MYOMA;

EID: 0033392781     PISSN: 09513590     EISSN: None     Source Type: Journal    
DOI: 10.3109/09513599909167584     Document Type: Article

References (31)

1. 1. Buttram Jr VC, Reiter, RC. Uterine leiomyomata: etiology, symptomatology, and management. Fertil Steril 1981;36:433-47
2. 2. Schally AV. The use of LHRH analogs in gynecology and tumor therapy. In Belfort, P, Pinotti JA, Eskes TKAB (eds) General Gynecology. Carnforth, UK: Parthenon Publishing, Vol 6, 3-22
3. 3. Adamson GD. Treatment of uterine fibroids: current findings with gonadotropin-releasing hormone agonists. Am J Obstet Gynecol 1992; 166:746-51
4. 4. Surrey ES. Steroidal and nonsteroidal 'add-back' therapy: extending safety and efficacy of gonadotropin-releasing hormone agonists in the gynecologic patient. Fertil Steril 1995;64:673-85
5. 5. Friedman, AJ, Fine C, Barbieri RL., et al. A randomized, double-blind trial of a gonadotropin-releasing hormone agonist (leuprolide) with or without medroxyprogesterone acetate in the treatment of leiomyomata uteri. Fertil Steril 1988;49: 404-9
6. 6. Friedman AJ. Treatment of leiomyomata uteri with short-term leuprolide followed by leuprolide plus estrogen-progestin hormone replacement therapy for 2 years: a pilot study. Fertil Steril 1989;51:526-8
7. 7. Maheux R, Lemay A, Blanchet P, et al. Maintained reduction of uterine leiomyoma following addition of hormonal replacement therapy to a monthly luteinizing hormone-releasing hormone agonist implant: a pilot study. Hum Reprod 1991;6:500-5
8. 8. Carr BR, Marshburn PB, Weatherall PT, et al. An evaluation of the effect of gonadotropin-releasing hormone analogs and medroxyprogesterone acetate on uterine leiomyomata volume by magnetic resonance imaging: a prospective, randomized, double blind, placebo-controlled, crossover trial. J Clin Endocrinol Metab 1993; 76:1217-23
9. 9. Friedman AJ, Daly M, Janeau-Norcross M, et al. Long-term medical therapy for leiomyomata uteri: a prospective, randomized study of leuprolide acetate depot plus either oestrogen-progestin or progestin 'add-back' for 2 years. Hum Reprod 1994;9:1618-25
10. 10. Friedman AJ, Lobel SM, Rein MS, Barbieri RL. Efficacy and safety considerations in women with uterine leiomyomas treated with gonadotropin-releasing hormone agonists: the estrogen threshold hypothesis. Am J Obstet Gynecol 1990;163:1114-19
11. 11. Wilson EA, Yang F, Rees ED. Estradiol and progesterone binding in uterine leiomyomata and in normal uterine tissues. Obstet Gynecol 1980;55: 20-4
12. 12. Schiff I, Tulchinsky D, Ryan K, et al. Plasma estriol and its conjugates following oral and vaginal administration of estriol to postmenopausal women: correlations with gonadotropin levels. Am J Obstet Gynecol 1980;138:1137-41
13. 13. Clark JH, Paszko Z, Peck Jr EJ. Nuclear binding and retention of the receptor estrogen complex: relation to the agonistic and antagonistic properties of estriol. Endocrinology 1977;100:91-6
14. 14. Englund DE, Elamsson KB, Johansson EDB. Bioavailability of oestriol. Acta Endocrinol 1982;99: 136-40
15. 15. Heimer GM. Estriol in the postmenopause. Acta Obstet Gynaecol Scand (Suppl) 1987;139:1-23
16. 16. Melamed M, Castano E, Notides AC, Sasson S. Molecular and kinetic basis for the mixed agonist/ antagonist activity of estriol. Mol Endocrinol 1997; 11:1868-78
17. 17. Tzingounis VA, Aksu MF, Greenblatt RB. Estriol in the management of the menopause. J Am Med Assoc 1978;239:1638-41
18. 18. Grasso A, Baraghini F, Barbieri C, et al. Endocrinological features and endometrial morphology in climacteric women receiving hormone replacement therapy. Maturitas 1982; 4:19-26
19. 19. Minaguchi H, Uemura T, Shirasu K, et al. Effect of estriol on bone loss in postmenopausal Japanese women: a multicentcr prospective open study. J Obstet Gynaecol Res 1996;22:259-65
20. 20. Tzingounis VA, Aksu MF, Greenblatt RB. The significance of oestriol in the management of the post-menopause. Acta Endocrinol 1980; 233(Suppl):45-50
21. 21. Lauritzen C. Results of a 5 year prospective study of estriol succinatc treatment in patients with climacteric complaints. Harm Metab Res 1987; 19:579-84
22. 22. Nakayama H, Yano T, Sagara Y, et al. Clinical usefulness of urinary CrossLaps as a sensitive marker of bone metabolism. Endocr J 1997;44:479-84
23. 23. Yang TS, Tsan SH, Chang SP, Ng HT. Efficacy and safety of estriol replacement therapy for climacteric women. Chin Med J (Taipei) 1995; 55:386-91
24. 24. Lindsay R, Hart DM, Maclcan A, et al. Bone losss during oestriol therapy in postmenopausal women. Maturitas 1979;1:279-85
25. 3 and calcium lactate on vertebral bone loss in early menopausal women. Maturitas 1997;28:11-17
26. 26. Gudmundsson JA, Ljunghall S, Bergqvist C, et al. Increased bone turnover during gonadotropin-releasing hormone superagonist-induced ovulation inhibition. J Clin Endocrinol Metab 1987;65: 159-63
27. 27. Raven P, Bergqvist A, Hansen MA, et al. Treatment of endometriosis with the luteinizing hormone releasing hormone agonist nafarelin. Effect on bone turnover and bone mass. Menopause 1994;1:11-17
28. 28. Heaney RP, Recker RR, Saville PD. Menopausal changes in bone remodeling. J Lab Clin Metab 1978;92:964-70
29. 29. Englund DE, Johansson EDB. Endometrial effect of oral cstriol treatment in postmenopausal women. Acta Obstet Gynaecol Scand 1980;59:449-51
30. 30. Punnonen R, Söderström K-O. The effect of oral estriol succinate therapy on the endometrial morphology in postmenopausal women: the significance of fractionation of the dose. Eur J Obstet Gynecol Reprod Biol 1983;14:217-24
31. 31. Montoneri C, Zarbo G, Garofalo A, Giardinella S. Effects of estriol administration on human postmenopausal endometrium. Clin Exp Obstet Gynecol 1987;14:178-81